Results 1 to 10 of about 381 (103)

Structural insights into the inhibition mechanism of fungal GWT1 by manogepix [PDF]

Nature Communications
Glycosylphosphatidylinositol (GPI) acyltransferase is crucial for the synthesis of GPI-anchored proteins. Targeting the fungal glycosylphosphatidylinositol acyltransferase GWT1 by manogepix is a promising antifungal strategy.
Wang Xiang, Hanmin Liu, Yaozong Li
exaly   +8 more sources

Rho2-dependent cell wall remodeling boosts the fungistatic activity of manogepix against Aspergillus fumigatus [PDF]

The Cell Surface
Fosmanogepix is a new antifungal agent currently undergoing phase 3 clinical trials. Its active moiety, manogepix, inhibits Gwt1 which is an enzyme essential for the assembly and attachment of glycosylphosphatidylinositol anchors to cell wall proteins ...
Sean Brazil, Isabel Kopp-Fouquet, Samuel Zen Kai Yap, Michael Carty, Johannes Wagener   +4 more
doaj   +5 more sources

Calcineurin Inhibitors Synergize with Manogepix to Kill Diverse Human Fungal Pathogens

Journal of Fungi (Basel, Switzerland), 2022
Invasive fungal infections have mortality rates of 30–90%, depending on patient co-morbidities and the causative pathogen. The frequent emergence of drug resistance reduces the efficacy of currently approved treatment options, highlighting an urgent need
Leah Cowen, Luke Whitesell, Sean D Liston   +2 more
exaly   +5 more sources

In Vitro Antifungal Activity of Manogepix and Other Antifungal Agents against South African Candida auris Isolates from Bloodstream Infections

Microbiology Spectrum, 2022
We determined the susceptibility of South African Candida auris bloodstream surveillance isolates to manogepix, a novel antifungal, and several registered antifungal agents. C. auris isolates were submitted to a reference laboratory between 2016 and 2017.
Nelesh Govender, Serisha Naicker, Tsidiso Maphanga   +2 more
exaly   +5 more sources

Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018–2019)

Journal of Global Antimicrobial Resistance, 2021
: Objectives: : Manogepix, the active moiety of the prodrug fosmanogepix, is a novel antifungal with activity against major fungal pathogens including Candida (except Candida krusei), Aspergillus and difficult-to-treat/rare moulds.
Michael Huband, Mariana Castanheira
exaly   +5 more sources

Manogepix demonstrates potent in vitro activity against Aspergillus, Coccidioides, Scopulariopsis/Microascus, Rasamsonia, and Purpureocillium species, including strains with in vitro resistance to other antifungals [PDF]

Antimicrobial Agents and Chemotherapy
Manogepix, the active moiety of the prodrug fosmanogepix, is a novel investigational agent in clinical trials that inhibits Gwt1, depleting glycosylphosphatidylinositol (GPI)-anchored mannoproteins critical for fungal cell wall integrity.
Nathan P. Wiederhold, Hoja P. Patterson, Carmita Sanders, Connie Canete-Gibas   +3 more
doaj   +3 more sources

Antifungal Susceptibility of Clinical Meyerozyma guillermondii Isolates Obtained Between 1994 and 2014: Original Research and Comparison with Published Data [PDF]

Pathogens
(1) Background: Meyerozyma guilliermondii is a yeast species widely distributed in the natural environment and one of the rare emerging pathogens capable of causing difficult to treat, severe infections.
Aleksandra Górzyńska, Daria Konarska, Agnieszka Korzeniowska-Kowal, Anna Wzorek, Bartosz Pencakowski, Urszula Nawrot   +5 more
doaj   +2 more sources

Establishment of epidemiological cutoff values against Purpureocillium lilacinum [PDF]

Journal of Clinical Microbiology
Purpureocillium lilacinum, a common environmental fungus, can cause hyalohyphomycosis with varied clinical manifestations. Mortality rates can reach 20% with invasive disease. P.
Dallas J. Smith, Marisa L. Winkler, Philippe J. Dufresne, Warda Memon, Julianne V. Kus, Lisa McTaggart, Yalong Li, Rodrigo Almeida-Paes, Gloria M. González, Huan Mei, Ruoyu Li, Jasmijn Jansen, Yinggai Song, Jos Houbraken, Ferry Hagen, Amir Seyedmousavi, Sean X. Zhang, Mariana Castanheira, Shawn R. Lockhart, Jochem B. Buil, Andrew M. Borman, Nathan P. Wiederhold   +21 more
doaj   +2 more sources

Multicenter surveillance of antifungal susceptibility of clinical Aspergillus isolates to conventional and novel antifungal agents in Taiwan, 2021–2023 [PDF]

Microbiology Spectrum
Periodic surveillance of antifungal susceptibility among Aspergillus isolates is essential to guide effective treatment. This multicenter study analyzed 550 clinical Aspergillus isolates collected in Taiwan from 2021 to 2023, primarily from the ...
Ming-I Hsieh, Pui-Ching Choi, Wan-Lin Wu, Yu-Fu Lin, Chi-Jung Wu   +4 more
doaj   +2 more sources

Echinocandin tolerance and persistence in vitro are regulated by calcineurin signaling in Candida glabrata [PDF]

mBio
Upon exposure to echinocandins, growing yeast cells begin to accumulate cell wall damage and eventually die, resulting in therapeutic effects. While resistance to echinocandins is well studied, tolerance and persistence mechanisms that may also ...
Abigail A. Harrington, Timothy J. Nickels, Kyle W. Cunningham   +2 more
doaj   +2 more sources